--(BUSINESS WIRE)--Acucela Inc., is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Acucela’s development pipeline include drug candidates and therapeutics for the treatment of retinitis pigmentosa, proliferative diabetic retinopathy, diabetic macular edema, AMD, Stargardt disease, cataracts and presbyopia. The company is also developing a monitoring device for neovascular retinal diseases, to be used directly by patients.
| Company: | Acucela Inc. | ||
| Headquarters Address: | Kasumigaseki Tokyu Building 4F, | ||
| 3-7-1 Kasumigaseki, Chiyoda-ku, | |||
| Tokyo | |||
| Japan | |||
| Main Telephone: | 1-206-805-8300 | ||
| Website: | |||
| Type of Organization: | A subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) | ||
| Industry: | Biotechnology, Medical Devices, Pharmaceutical | ||
| Key Executives: | CEO: Ryo Kubota, M.D., Ph.D. | ||
| Public Relations | |||
| Contact: | Michael Hasegawa | ||
| Phone: | +81-3-6550-8928 | ||
| Email: | |||
| Investor Relations | |||
| Contact: | John Gebhart | ||
| Phone: | +1-206-805-3972 | ||
| Email: |
